Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US

Contributed by: Business Wire

Logo

Tags

Oncology

Professional Services

Health

Finance

Clinical Trials

Pharmaceutical

Biotechnology

Zydus Lifesciences

More Like This

Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus

GlobeNewswire associated0

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry Disease

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

Merus Receives FDA extension of PDUFA for zenocutuzumab

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference